The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion and recommended granting a marketing authorization for Pluvicto (lutetium Lu 177 vipivotide tetraxetan), a radioligand therapy, in combination with androgen deprivation therapy with or without androgen receptor pathway inhibition, for the treatment of adult patients with progressive prostate-specific membrane antigen-positive, metastatic, castration-resistant prostate cancer who have been treated with AR pathway inhibition and taxane based chemotherapy.
Findings out of VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine, published in Pharmacological Research, show that a targeted small molecule inhibitor, IVMT-Rx-4, may prevent prostate tumors from spreading to an advanced and incurable stage in the bones.
